Over the last 12 months, 10x Genomics insiders reported no purchases and 22 sales totaling $9.9M across SEC Form 4 filings. 45% of those filings were made under pre-arranged 10b5-1 trading plans.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 26, 2026 | Saxonov SergeChief Executive Officer · O·D | ▼ Sale | 10,486 | $63.69 | $668K | -1% | plan · 3 tranches |
| Aug 24, 2026 | Saxonov SergeChief Executive Officer · O·D | ▼ Sale | 18,545 | $63.02 | $1.2M | -1.7% | — |
| Aug 24, 2026 | Taich AdamChief Financial Officer · O | ▼ Sale | 17,166 | $63.02 | $1.1M | -4.5% | — |
| Aug 24, 2026 | Hindson Benjamin J.See Remarks · O·D | ▼ Sale | 13,818 | $63.02 | $871K | -2.8% | — |
| Aug 24, 2026 | SULIMAN SHEHNAAZD | ▼ Sale | 2,207 | $63.65 | $140K | -7% | plan · 2 tranches |
| Aug 14, 2026 | Teichmann Sarah A.D | ▼ Sale | 7,551 | $57.25 | $432K | -21.2% | plan · 2 tranches |
| Aug 11, 2026 | STUELPNAGEL JOHN RD | ▼ Sale | 20,000 | $57.75 | $1.2M | -5.4% | 2 tranches |
| Jun 22, 2026 | Saxonov SergeChief Executive Officer · O·D | ▼ Sale | 30,000 | $34.44 | $1.0M | -2.6% | plan · 4 tranches |
| Jun 16, 2026 | SULIMAN SHEHNAAZD | ▼ Sale | 5,723 | $32.63 | $187K | -15.3% | plan · 2 tranches |
| May 22, 2026 | Saxonov SergeChief Executive Officer · O·D | ▼ Sale | 18,175 | $24.44 | $444K | -1.6% | plan |
| May 22, 2026 | Hindson Benjamin J.See Remarks · O·D | ▼ Sale | 11,595 | $24.44 | $283K | -2.3% | — |
| May 22, 2026 | Taich AdamChief Financial Officer · O | ▼ Sale | 15,098 | $24.44 | $369K | -3.8% | — |
| Apr 14, 2026 | Saxonov SergeChief Executive Officer · O·D | ▼ Sale | 5,000 | $24.56 | $123K | -0.4% | plan |
| Mar 24, 2026 | Saxonov SergeChief Executive Officer · O·D | ▼ Sale | 15,000 | $19.26 | $289K | -1.3% | plan · 2 tranches |
| Mar 2, 2026 | Saxonov SergeChief Executive Officer · O·D | ▼ Sale | 16,152 | $22.73 | $367K | -1.3% | plan · 2 tranches |
| Feb 25, 2026 | Teichmann Sarah A.D | ▼ Sale | 7,579 | $19.41 | $147K | -22.1% | plan |
| Feb 23, 2026 | Saxonov SergeChief Executive Officer · O·D | ▼ Sale | 9,632 | $18.58 | $179K | -0.9% | — |
| Feb 23, 2026 | Taich AdamChief Financial Officer · O | ▼ Sale | 8,968 | $18.58 | $167K | -3% | — |
| Feb 23, 2026 | Hindson Benjamin J.See Remarks · O·D | ▼ Sale | 7,826 | $18.58 | $145K | -1.8% | — |
| Nov 24, 2025 | Taich AdamChief Financial Officer · O | ▼ Sale | 11,888 | $19 | $226K | -3.8% | — |
| Nov 24, 2025 | Hindson Benjamin J.See Remarks · O·D | ▼ Sale | 8,283 | $19 | $157K | -1.9% | — |
| Nov 24, 2025 | Saxonov SergeChief Executive Officer · O·D | ▼ Sale | 13,261 | $19 | $252K | -1.3% | — |
| Aug 22, 2025 | Saxonov SergeChief Executive Officer · O·D | ▼ Sale | 9,348 | $13.79 | $129K | -1% | — |
| Aug 22, 2025 | Taich AdamChief Financial Officer · O | ▼ Sale | 22,315 | $13.79 | $308K | -6.7% | — |
| Aug 22, 2025 | Hindson Benjamin J.See Remarks · O·D | ▼ Sale | 7,486 | $13.79 | $103K | -1.7% | — |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? 10x Genomics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TXG feed.